Actively Recruiting
First-in-Human Trial of Intravenous BI 4060107 in Adults With Unresectable Advanced or Metastatic Solid Tumors
Led by AIMEDBIO · Updated on 2026-10-28
86
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the highest dose of a new medicine called BI 4060107 that adults with advanced, unresectable solid tumors can tolerate. This study includes adults who have tried all standard treatments and have no other options. BI 4060107 is being given to humans for the first time in this open-label, phase 1 trial. Participants are grouped by dose levels, starting with the lowest dose for the first group. If lower doses are tolerated, higher doses are given to later groups. The medicine is given intravenously, and after the first dose, participants stay overnight at the study site. Those who benefit and tolerate the treatment can continue for up to three years with regular visits. During the study, doctors monitor participants health, noting any problems possibly caused by BI 4060107. Assessments include checking for dose-limiting toxicities within 21 days and monitoring adverse events for up to 36 months. Blood samples are taken to study how the medicine behaves in the body. Participants visit the study site regularly for treatment and health evaluations throughout the study period.
CONDITIONS
Brief Title
A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here